JMP Securities Upgrades AN2 Therapeutics to Market Outperform, Announces $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan upgraded AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform, setting a price target of $6.
April 02, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AN2 Therapeutics was upgraded by JMP Securities from Market Perform to Market Outperform with a new price target of $6.
Upgrades by analysts, especially with a significant price target increase, typically lead to positive short-term price movements as they reflect a positive change in the analyst's view on the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100